If IL-10 immunotherapy is to be translated to humans as a potential treatment modality for retinopathy, local intraocular injection of anti-IL-10 antibodies or other IL-10 inhibitors, similar to anti-VEGF injections for AMD patients, may be desirable to minimize the systemic effects in non-ocular vascular beds. The gene discussed is IL10; the disease is retinal disorder.